Ampersand Biomedicines

About Ampersand Biomedicines

Ampersand Biomedicines is a company focused on creating and programming therapeutics to treat diseases with high efficacy while maintaining safety and tolerability. Their proprietary Address, Navigate, Determine (AND)™ Platform designs next-generation modular medicines, called AND-Body™ Therapeutics, which target disease sites precisely without affecting healthy tissues, thus minimizing side effects.

Products & Services

AND-Body™ Therapeutics:Novel programmable, multi-specific medicines designed to act at the site of disease by combining localizing elements for precision targeting and actuators for disease modification, improving target engagement while avoiding off-tissue side effects.

AND™ Platform:A computationally powered platform that identifies ideal drug localization addresses and informs the design of AND-Body Therapeutics for optimal therapeutic effect, targeting disease precisely.

Specialties

Programmable Medicines Disease-Specific Precision Targeting Therapeutic Localization Computational Drug Design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 65000000 MR: - FA: $65 million FAN: 65000000	D: 2025-03-19 FD: 2025-03-19	2 investors

Series B Latest

2025-03-19

$65.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jason Gardner, DPhil

CEO and Director

D

Daniël Blom, PhD

Chief Scientific Officer (CSO)

V

Volker Lang, PhD

Managing Director, Pilsen Site

M

Melanie Morel-Ferris

Vice President, Finance

N

Natalie Lissy, PhD, JD

Vice President, Head of Legal

C

Claudia Wurzenberger

Vice President, Project Management

View 16 more team members with Pro

Unlock Full Team Directory

Recent News